Mark Versavel Email and Phone Number
Mark Versavel work email
- Valid
- Valid
- Valid
Mark Versavel personal email
- Valid
Mark Versavel phone numbers
Clinical pharma consultant as President of vZenium LLC. Currently appointed as clinical consultant for Afasci, Alzheon, Bial, Biodol, Noema and Vigil Neuro. Former CMO and Senior VP at Eliem Therapeutics. Scientific advisory board member at Confo. Providing clinical development support to biotech and pharmaceutical companies, building on >30 years experience in clinical development and medical affairs in multiple CNS indications including stroke, neuropathic pain, multiple sclerosis, Parkinson's, restless legs, Huntington's, Alzheimer's, epilepsy, autism, schizophrenia, bipolar disorder and depression. Track record of achievements through multi-disciplinary team-leadership with a cooperative leadership style, motivating teams to top performance and persisting though difficult periods, always looking for solutions and creative ways to move the project forward. Strong analytical and judgment skills and capability to make decisions in the face of uncertainty. Flexibility and capacity to learn and succeed in new situations and cultures, with extensive international experience (Belgium, Netherlands, Germany, France, USA).•Bringing Alzheon's drug ALZ-801 to Phase 2-3 in Alzheimer's Disease.•Completed 2 Phase 2 trials with Z160 in neuropathic pain at Zalicus, and demonstrated efficacy of Z944 in laser evoked pain model.•Created pharmaco-EEG and neuropsychological test unit, performed validation studies that led to PhD thesis on the use of psychometric tests in healthy volunteers.•Clinical pharmacology lead for nimodipine (Nimotop®), ipsapirone CR, BAYx 3702, metrifonate•Clinical development for ziprasidone (Geodon®) in schizophrenia and bipolar disorder, pregabalin (Lyrica®) in epilepsy and neuropathic pain, sumanirole in Parkinson’s disease and Restless Legs Syndrome, AMPA antagonist in stroke•Medical Affairs and Phase IV experience with eslicarbazepine acetate (Aptiom®) in epilepsy, eszopiclone (Lunesta®) in insomnia, Lyrica® and gabapentin (Neurontin®) in neuropathic pain and epilepsy, Rebif® and Betaferon® / Betaseron® in MS,
-
Fractional CmoConsano Bio Nov 2024 - Present
-
PresidentVzenium Llc Mar 2014 - PresentNeurologic and psychiatric diseases are amongst the leading causes of disability. Neuroscience is making rapid progress and new drugs are being discovered that promise help for patients, doctors and society.vZenium is a life science consulting firm created to assist teams in small and large pharmaceutical companies to manage the development of new treatments that make SenZe for physicians and patients.This approach starts with innovation and creativity at the idea phase, ensures quality medical oversight during the planning and conduct of clinical research, provides expertise in negotiations with regulators, and thinks strategically beyond initial target labels to expand the market by working and communicating with the scientific community.vZenium is a project-driven organization, helping you with a strong product vision that motivates teams to succeed in the face of uncertainty.
-
CmoEliem Therapeutics Mar 2023 - Oct 2023Bellevue, Washington, Us -
Interim CmoEliem Therapeutics Jan 2022 - Oct 2023Bellevue, Washington, Us
-
Senior Vp ClinicalEliem Therapeutics Mar 2021 - Jan 2022Bellevue, Washington, Us
-
Chief Medical OfficerNeurobo Pharmaceuticals, Inc. Feb 2018 - Jan 2021Boston, Massachusetts, UsDeveloping proprietary treatments for neurodegeneraative disorders such as Alzheimer's disease, and neuropathic pain using botanicals -
Co FounderViepage Jul 2014 - Dec 2020Viepage LLC is developing CalendU, a calendar app for better organization of multiple life and work activities. Today Viepage has 5 LOI's signed, 2 new investors on board and it has a demo ready to show, while it is still looking for funds to get the product finished and launched. Find more information on www.calendutheapp.com
-
Chief Medical OfficerCavion, Inc. Mar 2019 - Aug 2019Developing CX-8998 in essentiel tremor and epilepsy.
-
PrincipalAkta Pharmaceutical Development™ (Aktapd) Mar 2014 - Nov 2015akta Pharmaceutical DevelopmentTM (aktaPD) is a progressive international company engaged in the design, development, and commercialization of treatments for diseases. The company is comprised of a consortium of experts with broad expertise in all development phases of multiple therapeutic areas. aktaPD has secured its place as the pharmaceutical development leader for academic, government, biopharmaceutical, and private investment communities.aktaPD delivers practical, yet innovative development plans that eclipse business modelsfocused on standard safety and efficacy endpoints. Their value-centric, interconnected, andstage-appropriate business-to-stakeholder (B2S) approach maximizes a client’s opportunityfor proof-of-concept to marketability. -
Chief Medical OfficerAlzheon, Inc. Dec 2013 - Sep 2015Framingham, Ma, UsClinical development of ALZ-801 as potential first in class disease modifying agent in Alzheimer's disease. -
Vp Clinical ResearchZalicus Incorporated Sep 2012 - Nov 2013Leading clinical development and operations for N-type Ca channel antagonist (2 Phase II studies starting) and T-type Ca channel antagonist (currently in Phase I)
-
Vice President Cns, Clinical Development And Medical AffairsSunovion Pharmaceuticals Inc. Jul 2009 - Jun 2012Marlborough, Ma, UsLeading CNS clinical development Phases I-IV, including medical affairs activities. Phase III-IV development of eslicarbazepine acetate in epilepsy. Early development in pai n and schizophrenia. Sunovion was previously known as Sepracor. -
Executive Medical Director Clinical Research CnsSunovion Pharmaceuticals Inc. Feb 2008 - Jul 2009Marlborough, Ma, UsMedical lead for NDA submission, initiation of monotherapy studies and publication activities with eslicarbazepine acetate in epilepsy.
-
Chairman Of The Board Of DirectorsFrench-American School Of Rhode Island Sep 2004 - Jun 2009Providence, Ri, UsLed the Board in providing oversight to the school's function. Supported creation of Middle School, improved Board organization through committees, increased focus on fundraising and performance evaluation. -
Senior Director Clinical Development NeurosciencePfizer Aug 1999 - Feb 2008New York, New York, UsGlobal Clinical Lead for ziprasidone R&D studies in bipolar disorder and schizophrenia -
Core ClinicianSchering Ag Oct 1995 - Jul 1999Lead Phase II development of AMPA antagonist in stroke.
-
Medical Director Phase I-IiPharmacon Research Mar 1995 - Sep 1995Leading Phase I-II studies in Germany / Berlin
-
Medical Director Phase IParexel Sep 1994 - Feb 1995Durham, North Carolina, UsMedical Head of Phase I institution in Berlin -
Projektleiter Klinische PharmakologieBayer Jan 1989 - Aug 1994Leverkusen, North Rhine-Westphalia, DePlanned and conducted Phase I studies with nimodipine, ipsapirone, metrifonate. Established and validated pharmaco EEG and computerized cognitive testing in the Phase I unit. -
Assistent NeurologyUniversitaetsklinikum Grosshadern, Muenchen Jan 1988 - Dec 1988In-patient medical care with focus on epilepsy and Parkinson's disease.
-
Scientific AssistantUniversiteit Leuven, Belgium Jan 1987 - Dec 1987Investigated neurophysiology of curvature processing in cat visual cortex
-
Assistent NeurosurgerySlotervaartziekenhuis Amsterdam Jun 1986 - Dec 1986Assisting neurosurgical procedures with a focus on spinal surgery. Pre-and postoperative patient care.
-
Assistent Surgery / Neurosurgery / NeurologyUniversitair Ziekenhuis Antwerpen Sep 1983 - May 1986Assisting neurosurgical procedures. Pre-and postoperative patient care including pain clinic.
Mark Versavel Skills
Mark Versavel Education Details
-
University Of Michigan - Stephen M. Ross School Of BusinessBusiness Administration -
Humboldt-Universität Zu BerlinClinical Pharmacology
-
University Of AntwerpMedicine
-
Onze-Lieve-Vrouw-Van-Lourdescollege EdegemLatin And Mathematics
-
Basisschool Abraham Hans, Kontich
Frequently Asked Questions about Mark Versavel
What company does Mark Versavel work for?
Mark Versavel works for Consano Bio
What is Mark Versavel's role at the current company?
Mark Versavel's current role is President at vZenium LLC, Fractional CMO at Consano Bio.
What is Mark Versavel's email address?
Mark Versavel's email address is mv****@****ail.com
What is Mark Versavel's direct phone number?
Mark Versavel's direct phone number is +178122*****
What schools did Mark Versavel attend?
Mark Versavel attended University Of Michigan - Stephen M. Ross School Of Business, Humboldt-Universität Zu Berlin, University Of Antwerp, Onze-Lieve-Vrouw-Van-Lourdescollege Edegem, Basisschool Abraham Hans, Kontich.
What are some of Mark Versavel's interests?
Mark Versavel has interest in Electronics, Education, Arts And Culture, Science And Technology, Music, Sports, Movies, Health.
What skills is Mark Versavel known for?
Mark Versavel has skills like Clinical Development, Clinical Trials, Neurology, Pharmaceutical Industry, Clinical Research, Biotechnology, Neuroscience, Drug Development, Life Sciences, Cro, Medical Affairs, Pharmacology.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial